MGCD0103

mocetinostat · Mirati Therapeutics Inc.

Drug timelines are a Plus or Pro feature.

8 regulatory and trial events tracked for MGCD0103, covering 2015-01-08 to 2015-07-01. Get the full timeline:

Most recent: Clinical Trial Update: A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia [Phase 2]